Young R C, Von Hoff D D, Gormley P, Makuch R, Cassidy J, Howser D, Bull J M
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1539-44.
cis-Dichlorodiammineplatinum(II) (cis-platinum) was used in the treatment of 25 patients with advanced ovarian adenocarcinoma refractory to alkylating agents. Seven of 24 evaluable patients (29%) responded to cis-platinum (one complete response and six partial responses). Life-table analysis of survival indicates that patients responding to therapy survive longer than those who fail to respond (9 months versus 3.2 months) (P = 0.014). In previously treated patients given 70 mg/m2 iv with forced diuresis, there was substantial nausea and vomiting (100%), hematologic toxicity (67%), and renal toxicity (34%). A review of the single-agent activity of cis-platinum in other ovarian cancer studies indicates an overall response rate of 25% (40 of 161 patients). At least nine combination chemotherapy studies utilizing cis-platinum are in progress, and preliminary information from several of these is encouraging and suggests that cis-platinum-containing combinations may have a major role in the treatment of ovarian adenocarcinoma.
顺二氯二氨铂（II）（顺铂）用于治疗25例对烷化剂耐药的晚期卵巢腺癌患者。24例可评估患者中有7例（29%）对顺铂有反应（1例完全缓解，6例部分缓解）。生存的生命表分析表明，对治疗有反应的患者比无反应的患者存活时间更长（9个月对3.2个月）（P = 0.014）。在先前接受治疗的患者中，静脉注射70 mg/m²并强制利尿，出现了严重的恶心和呕吐（100%）、血液学毒性（67%）和肾毒性（34%）。对其他卵巢癌研究中顺铂单药活性的综述表明，总体缓解率为25%（161例患者中的40例）。至少有九项使用顺铂的联合化疗研究正在进行中，其中几项的初步信息令人鼓舞，表明含顺铂的联合方案可能在卵巢腺癌的治疗中发挥重要作用。
